• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

AJMC in the Press, October 14, 2016

Article

Coverage of our peer-reviewed research in the healthcare and mainstream press.

In the October 3, 2016, edition of Medical Economics, Mark L. Fuerst discussed the commentary in a special issue of The American Journal of Managed Care on novel direct-acting antivirals (DAAs). Darius Lakdawalla, PhD, of the University of Southern California’s Schaeffer Center for Health Policy and Economics, wrote that cost-sharing plans that impose large out-of-pocket costs on DAAs for patients with hepatitis C virus (HCV) are “suboptimal solutions,” because they impose financial burdens on patients “at a time when they are least able to cope with them.” For the rest of the special issue on policy questions surrounding HCV treatment and cost-sharing, click here.

Related Videos
Benjamin Chen, MD, PhD
Benjamin Chen, MD, PhD
Lynae Darbes, PhD
Bridgette Picou, LVN, ACLPN, The Well Project
Lynae Darbes, PhD
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Annie Antar, MD, PhD, Johns Hopkins Medicine
Annie Antar, MD, PhD, Johns Hopkins Medicine
Jared Baeten
Jared Baeten
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.